Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to...
Saved in:
| Published in | Nature communications Vol. 13; no. 1; pp. 2023 - 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
19.04.2022
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on
ASCL1
,
NEUROD1
,
POU2F3
,
YAP1
, and
ATOH1
expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have
RB1
,
NOTCH
, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents.
Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical implications of neuroendocrine subtypes in metastatic and relapsed tumors, and the extent to which the subtype distribution is recapitulated in patient-derived models remains unclear. Here, the authors integrated genomics and transcriptomics on 100 small cell cancers from a range of metastatic sites finding complex intra- and intertumoral heterogeneity, notably not recapitulated in patient-derived model systems, and distinct therapeutic vulnerabilities associated with neuroendocrine subtypes. |
|---|---|
| AbstractList | Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents.Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents. Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1 , NEUROD1 , POU2F3 , YAP1 , and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1 , NOTCH , and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents. Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical implications of neuroendocrine subtypes in metastatic and relapsed tumors, and the extent to which the subtype distribution is recapitulated in patient-derived models remains unclear. Here, the authors integrated genomics and transcriptomics on 100 small cell cancers from a range of metastatic sites finding complex intra- and intertumoral heterogeneity, notably not recapitulated in patient-derived model systems, and distinct therapeutic vulnerabilities associated with neuroendocrine subtypes. Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents.Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical implications of neuroendocrine subtypes in metastatic and relapsed tumors, and the extent to which the subtype distribution is recapitulated in patient-derived models remains unclear. Here, the authors integrated genomics and transcriptomics on 100 small cell cancers from a range of metastatic sites finding complex intra- and intertumoral heterogeneity, notably not recapitulated in patient-derived model systems, and distinct therapeutic vulnerabilities associated with neuroendocrine subtypes. Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1 , NEUROD1 , POU2F3 , YAP1 , and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1 , NOTCH , and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents. Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents. Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical implications of neuroendocrine subtypes in metastatic and relapsed tumors, and the extent to which the subtype distribution is recapitulated in patient-derived models remains unclear. Here, the authors integrated genomics and transcriptomics on 100 small cell cancers from a range of metastatic sites finding complex intra- and intertumoral heterogeneity, notably not recapitulated in patient-derived model systems, and distinct therapeutic vulnerabilities associated with neuroendocrine subtypes. |
| ArticleNumber | 2023 |
| Author | Velez, Moises J. Mulford, Deborah Rajan, Arun El Meskini, Rajaa Atkinson, Devon Roper, Nitin Guha, Udayan Manukyan, Irena Rajapakse, Vinodh Takahashi, Nobuyuki Lissa, Delphine Desai, Parth Weaver Ohler, Zoe Schultz, Christopher W. Nichols, Samantha Thomas, Anish Vilimas, Rasa Sciuto, Linda Chen, Yuanbin |
| Author_xml | – sequence: 1 givenname: Delphine surname: Lissa fullname: Lissa, Delphine organization: Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI – sequence: 2 givenname: Nobuyuki surname: Takahashi fullname: Takahashi, Nobuyuki organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI, Medical Oncology Department, Center Hospital, National Center for Global Health and Medicine – sequence: 3 givenname: Parth surname: Desai fullname: Desai, Parth organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 4 givenname: Irena orcidid: 0000-0003-2437-0500 surname: Manukyan fullname: Manukyan, Irena organization: Laboratory of Pathology, Center for Cancer Research, NCI – sequence: 5 givenname: Christopher W. surname: Schultz fullname: Schultz, Christopher W. organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 6 givenname: Vinodh surname: Rajapakse fullname: Rajapakse, Vinodh organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 7 givenname: Moises J. surname: Velez fullname: Velez, Moises J. organization: Department of Pathology, University of Rochester Medical Center – sequence: 8 givenname: Deborah surname: Mulford fullname: Mulford, Deborah organization: Department of Medicine, University of Rochester Medical Center – sequence: 9 givenname: Nitin surname: Roper fullname: Roper, Nitin organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 10 givenname: Samantha surname: Nichols fullname: Nichols, Samantha organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 11 givenname: Rasa surname: Vilimas fullname: Vilimas, Rasa organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 12 givenname: Linda surname: Sciuto fullname: Sciuto, Linda organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI – sequence: 13 givenname: Yuanbin surname: Chen fullname: Chen, Yuanbin organization: Cancer and Hematology Centers of Western Michigan – sequence: 14 givenname: Udayan orcidid: 0000-0003-1087-9218 surname: Guha fullname: Guha, Udayan organization: Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI – sequence: 15 givenname: Arun orcidid: 0000-0003-2776-3385 surname: Rajan fullname: Rajan, Arun organization: Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI – sequence: 16 givenname: Devon orcidid: 0000-0002-6675-1531 surname: Atkinson fullname: Atkinson, Devon organization: Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research – sequence: 17 givenname: Rajaa orcidid: 0000-0003-3238-7038 surname: El Meskini fullname: El Meskini, Rajaa organization: Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research – sequence: 18 givenname: Zoe orcidid: 0000-0002-6287-2504 surname: Weaver Ohler fullname: Weaver Ohler, Zoe organization: Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research – sequence: 19 givenname: Anish orcidid: 0000-0003-3293-3115 surname: Thomas fullname: Thomas, Anish email: anish.thomas@nih.gov organization: Developmental Therapeutics Branch, Center for Cancer Research, NCI |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35440132$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ustu3SAQtapUTZrmB7qokLrpxi0vG7OpVEXNQ4rUTfYIw-ByZcMt2Kny98Fx0iZZhMUwwDlHZ4Z5Xx2EGKCqPhL8lWDWfcuc8FbUmNKayoaIWr6pjijmpCaCsoMn-WF1kvMOl8Uk6Th_Vx2yhnNMGD2q_l7ADCkOEMDPtyg6FGBJEYKNJvkAaE465JLuZx-DHlGe9QwZ-YAmmPV68gblSY8jMlDCuIQBGR0MpIx0sGhfEBDm2kLyN2DRFC2M-UP11ukxw8nDflxdn_28Pr2or36dX57-uKpNi9u51pJbCQZMy6gUtHHS2NbJvu-gocJorB0HSV2DJe64Ma2wTnJBrWxLpOy4utxkbdQ7tU9-0ulWRe3V_UVMg9KpVDCCor3AraM9MCy4a2xHjJCN0E5iA5qZovV909ov_QTWlKKSHp-JPn8J_rca4o2SmHRdy4vAlweBFP8skGc1-bw2TQeIS1a0bWjBYbZCP7-A7uKSSv83FMdd063VfXrq6J-Vx-8tgG4DmBRzTuCU8euPxdWgHxXBah0mtQ2TKsOk7odJyUKlL6iP6q-S2EbKBRwGSP9tv8K6A99i3qI |
| CitedBy_id | crossref_primary_10_1016_j_jbiotec_2024_01_010 crossref_primary_10_1016_j_celrep_2024_114606 crossref_primary_10_1002_mco2_70059 crossref_primary_10_1016_j_jtho_2023_06_009 crossref_primary_10_1158_2159_8290_CD_22_0620 crossref_primary_10_3390_cancers16061177 crossref_primary_10_1158_1078_0432_CCR_24_0104 crossref_primary_10_1038_s41388_023_02929_7 crossref_primary_10_1136_jcp_2023_209109 crossref_primary_10_1016_j_omtn_2024_102250 crossref_primary_10_1016_j_xcrm_2024_101610 crossref_primary_10_3390_cancers16162795 crossref_primary_10_1038_s41698_024_00739_y crossref_primary_10_1016_j_isci_2024_111730 crossref_primary_10_1158_1078_0432_CCR_23_1159 crossref_primary_10_1002_mco2_370 crossref_primary_10_3390_cancers15030990 crossref_primary_10_1016_j_lungcan_2024_108071 crossref_primary_10_1001_jamaoncol_2023_4025 crossref_primary_10_1126_sciadv_ado4618 crossref_primary_10_1158_1541_7786_MCR_23_0002 crossref_primary_10_1038_s41416_024_02821_5 crossref_primary_10_1053_j_seminoncol_2022_06_003 crossref_primary_10_1038_s41571_024_00914_x crossref_primary_10_1016_j_tice_2025_102756 crossref_primary_10_1016_j_ctarc_2023_100684 crossref_primary_10_1038_s41392_023_01419_2 crossref_primary_10_1007_s10555_023_10121_2 crossref_primary_10_1007_s11654_022_00437_w crossref_primary_10_1016_j_ccell_2022_04_014 crossref_primary_10_1016_j_humpath_2023_08_003 crossref_primary_10_1007_s00262_024_03829_9 crossref_primary_10_1021_acs_est_2c08838 crossref_primary_10_3389_pore_2024_1611743 crossref_primary_10_1111_pin_13426 crossref_primary_10_1007_s13577_024_01109_3 crossref_primary_10_1016_j_jtho_2022_11_008 crossref_primary_10_1038_s43018_022_00456_0 crossref_primary_10_1007_s10555_024_10207_5 crossref_primary_10_1038_s41392_024_01981_3 crossref_primary_10_1038_s41598_024_52687_z crossref_primary_10_1126_sciadv_adk2082 crossref_primary_10_1200_OA_0000000000000001 crossref_primary_10_1038_s41746_024_01003_0 crossref_primary_10_1007_s00428_024_03754_3 crossref_primary_10_1016_j_molmed_2024_08_004 crossref_primary_10_1038_s42003_025_07605_y crossref_primary_10_1136_jitc_2024_008974 crossref_primary_10_1016_j_ccell_2024_01_010 crossref_primary_10_1038_s41556_023_01210_z crossref_primary_10_1126_science_adj1415 crossref_primary_10_1158_2159_8290_CD_22_0796 crossref_primary_10_1111_cas_16275 crossref_primary_10_1007_s00108_022_01362_4 crossref_primary_10_1186_s13073_025_01438_4 crossref_primary_10_1158_1541_7786_MCR_22_0881 crossref_primary_10_3390_ijms25084208 |
| Cites_doi | 10.1038/s41467-018-06162-9 10.18632/oncotarget.20572 10.1186/1471-2407-11-529 10.1158/1078-0432.CCR-19-3841 10.21037/tlcr.2018.02.02 10.1002/cncr.24853 10.2217/fon-2017-0706 10.1016/j.ccell.2020.05.001 10.1016/j.jtho.2020.05.008 10.1016/j.cmet.2018.06.005 10.1172/JCI91190 10.1016/j.ccell.2019.06.005 10.1038/s43018-020-0046-2 10.1158/2159-8290.CD-19-0094 10.1016/j.celrep.2019.05.057 10.1016/j.jtho.2020.09.009 10.1093/bioinformatics/btp616 10.1158/2159-8290.CD-19-0582 10.1016/j.ccell.2016.12.005 10.1016/j.immuni.2013.10.003 10.1158/1078-0432.CCR-17-2655 10.1016/j.jtho.2020.11.006 10.1038/nature14664 10.1016/j.ydbio.2018.12.025 10.1158/2159-8290.CD-17-0935 10.1186/1471-2105-14-7 10.18632/oncotarget.10644 10.1038/s41598-017-17204-5 10.1038/s42003-021-01842-7 10.1200/JCO.2017.76.6915 10.1073/pnas.1410419111 10.1016/j.jtho.2018.10.003 10.1038/nrc.2017.106 10.1016/j.jtho.2019.04.026 10.1038/s41417-021-00318-4 10.1016/j.chest.2018.07.029 10.1093/bioinformatics/btr260 10.1007/978-1-4939-7493-1_12 10.1016/j.ccell.2020.12.014 10.1056/NEJMoa1809064 10.1101/gad.276304 10.1016/j.jtho.2019.10.013 10.1038/cr.2009.5 10.1371/journal.pcbi.1007343 10.1038/nmeth.3337 10.1172/JCI139929 10.1016/j.ccell.2017.09.003 10.1038/s41568-019-0133-9 10.1007/978-1-4939-1050-2_3 10.1073/pnas.1517188113 10.1016/j.molcel.2016.05.012 10.1038/s41388-020-1367-4 10.1186/s13059-016-1092-z 10.18632/oncotarget.20621 10.1016/S1470-2045(10)70295-3 10.1038/s41586-020-1943-3 10.1016/j.celrep.2016.06.081 10.1093/jnci/djw122 10.1016/j.ccell.2020.06.012 10.1097/PAP.0000000000000162 10.1056/NEJMoa1916623 10.1016/j.ccell.2014.10.019 10.1016/j.celrep.2020.108296 10.1016/j.ccell.2017.01.006 10.1016/j.pharmthera.2019.05.009 10.1038/s41467-019-13043-2 10.1038/nature22323 10.1101/gad.314815.118 10.1038/s41571-020-0340-z 10.3892/ol.2012.792 10.1038/nm.4045 10.1158/1078-0432.CCR-18-4140 10.1158/2159-8290.CD-14-0001 10.2139/ssrn.3891794 10.1038/celldisc.2015.26 10.1038/s41467-019-11371-x 10.1038/s41467-021-24164-y 10.1016/j.ccell.2021.02.014 10.1158/1538-7445.AM2019-CT073 10.7554/eLife.49020 10.1101/2020.09.13.291328 10.14694/EdBook_AM.2015.35.92 10.1101/2021.01.22.427865 |
| ContentType | Journal Article |
| Copyright | This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 – notice: 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. – notice: This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-022-29517-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_2b706f2be3074f5d81c7957af90cea3c PMC9018864 35440132 10_1038_s41467_022_29517_9 |
| Genre | Journal Article Research Support, N.I.H., Intramural |
| GrantInformation_xml | – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) grantid: ZIA BC 011793 funderid: https://doi.org/10.13039/100000054 – fundername: Intramural NIH HHS grantid: ZIA BC011793 – fundername: ; grantid: ZIA BC 011793 |
| GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c606t-a94d9ecec6329725f9cd6f9bb8e527ca0af4e92f509084cc67df9472d9647223 |
| IEDL.DBID | M48 |
| ISSN | 2041-1723 |
| IngestDate | Wed Aug 27 01:28:55 EDT 2025 Thu Aug 21 14:12:13 EDT 2025 Thu Jul 10 23:53:54 EDT 2025 Sat Aug 23 12:29:35 EDT 2025 Mon Jul 21 06:03:37 EDT 2025 Thu Apr 24 22:58:47 EDT 2025 Tue Jul 01 04:17:47 EDT 2025 Fri Feb 21 02:38:46 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c606t-a94d9ecec6329725f9cd6f9bb8e527ca0af4e92f509084cc67df9472d9647223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2437-0500 0000-0003-2776-3385 0000-0003-1087-9218 0000-0003-3238-7038 0000-0003-3293-3115 0000-0002-6675-1531 0000-0002-6287-2504 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41467-022-29517-9 |
| PMID | 35440132 |
| PQID | 2652408582 |
| PQPubID | 546298 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2b706f2be3074f5d81c7957af90cea3c pubmedcentral_primary_oai_pubmedcentral_nih_gov_9018864 proquest_miscellaneous_2652864034 proquest_journals_2652408582 pubmed_primary_35440132 crossref_citationtrail_10_1038_s41467_022_29517_9 crossref_primary_10_1038_s41467_022_29517_9 springer_journals_10_1038_s41467_022_29517_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-19 |
| PublicationDateYYYYMMDD | 2022-04-19 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Bottger (CR23) 2019; 27 Balanis (CR8) 2019; 36 Elyada (CR50) 2019; 9 Chang (CR57) 2018; 24 Farago (CR28) 2019; 9 Gazdar, Bunn, Minna (CR2) 2017; 17 Liberzon (CR83) 2011; 27 Chung (CR90) 2019; 79 Simpson (CR22) 2020; 1 Takahashi, Surolia, Thomas (CR77) 2020; 26 Beltran (CR17) 2016; 22 Chen, Khodadoust, Liu, Newman, Alizadeh (CR64) 2018; 1711 CR73 Rudin (CR4) 2019; 19 Huang (CR69) 2021; 131 Hendry (CR87) 2017; 24 Nakazawa (CR78) 2012; 4 Howlader (CR1) 2020; 383 Xu, Lamouille, Derynck (CR47) 2009; 19 Chalishazar (CR67) 2019; 25 Bluemn (CR16) 2017; 32 Borromeo (CR35) 2016; 16 Mollaoglu (CR43) 2017; 31 Gazdar, Carney, Nau, Minna (CR18) 1985; 45 Owonikoko (CR75) 2021; 16 Newman (CR25) 2015; 12 Thomas, Pommier (CR52) 2016; 8 Cardnell (CR72) 2017; 8 Schreiber (CR6) 2010; 116 Hanzelmann, Castelo, Guinney (CR82) 2013; 14 Baine (CR38) 2020; 15 CR9 CR48 Stewart, Gay (CR21) 2020; 1 Huang (CR37) 2018; 32 Wooten (CR42) 2019; 15 Ping (CR51) 2021; 28 Pefani (CR41) 2016; 63 Anastassiou (CR49) 2011; 11 Zhong, Fu, Pan, Yu, Wang (CR39) 2019; 446 CR44 Bankhead (CR88) 2017; 7 Lundberg (CR54) 2020; 39 Christensen (CR19) 2014; 26 Augustyn (CR45) 2014; 111 Lim (CR24) 2017; 545 Feldman, Wolfe (CR85) 2014; 1180 Jensen, Gazdar, Cuttitta, Russell, Linnoila (CR20) 1990; 50 Hidalgo (CR76) 2014; 4 Wagner (CR32) 2018; 9 Drapkin (CR29) 2018; 8 Polley (CR34) 2016; 108 Marjanovic (CR70) 2020; 38 Carney (CR3) 1985; 45 Horn (CR59) 2018; 379 Quintanal-Villalonga (CR7) 2020; 17 Robinson, McCarthy, Smyth (CR81) 2010; 26 CR14 CR13 Timmerman (CR46) 2004; 18 CR10 Owonikoko (CR74) 2020; 15 CR53 Huang (CR68) 2018; 28 Ready (CR58) 2019; 14 Zhang (CR15) 2018; 7 Acs (CR89) 2019; 10 Bindea (CR60) 2013; 39 Senbabaoglu (CR61) 2016; 17 Alexandrov (CR71) 2020; 578 Ireland (CR31) 2020; 38 Cai, Wang, Li, Lin, Yu (CR80) 2018; 14 Ayers (CR62) 2017; 127 Murai, Thomas, Miettinen, Pommier (CR56) 2019; 201 McColl (CR36) 2017; 8 Best (CR65) 2020; 15 George (CR30) 2015; 524 Nishio (CR40) 2016; 113 CR26 Tlemsani (CR33) 2020; 33 Cai (CR66) 2021; 4 Gardner (CR55) 2017; 31 Thomas, Pattanayak, Szabo, Pinsky (CR5) 2018; 154 Ren (CR79) 2016; 7 CR63 Cuzick (CR84) 2011; 12 Thomas (CR12) 2019; 14 Thomas (CR11) 2018; 36 Gazdar, Carney, Nau, Minna (CR86) 1985; 45 Gay (CR27) 2021; 39 N Howlader (29517_CR1) 2020; 383 KLSR Simpson (29517_CR22) 2020; 1 YH Huang (29517_CR37) 2018; 32 ND Marjanovic (29517_CR70) 2020; 38 J George (29517_CR30) 2015; 524 K Nakazawa (29517_CR78) 2012; 4 NG Balanis (29517_CR8) 2019; 36 LB Alexandrov (29517_CR71) 2020; 578 MT Chang (29517_CR57) 2018; 24 29517_CR73 SA Best (29517_CR65) 2020; 15 TK Owonikoko (29517_CR75) 2021; 16 S Hendry (29517_CR87) 2017; 24 BJ Drapkin (29517_CR29) 2018; 8 MD Borromeo (29517_CR35) 2016; 16 P Bankhead (29517_CR88) 2017; 7 DN Carney (29517_CR3) 1985; 45 SM Jensen (29517_CR20) 1990; 50 AT Feldman (29517_CR85) 2014; 1180 B Chen (29517_CR64) 2018; 1711 W Zhang (29517_CR15) 2018; 7 29517_CR9 K McColl (29517_CR36) 2017; 8 AF Gazdar (29517_CR2) 2017; 17 J Murai (29517_CR56) 2019; 201 29517_CR26 C Tlemsani (29517_CR33) 2020; 33 Y Senbabaoglu (29517_CR61) 2016; 17 CM Gay (29517_CR27) 2021; 39 M Nishio (29517_CR40) 2016; 113 29517_CR63 B Acs (29517_CR89) 2019; 10 MD Chalishazar (29517_CR67) 2019; 25 AF Gazdar (29517_CR86) 1985; 45 LA Timmerman (29517_CR46) 2004; 18 Q Ping (29517_CR51) 2021; 28 F Huang (29517_CR69) 2021; 131 A Lundberg (29517_CR54) 2020; 39 M Hidalgo (29517_CR76) 2014; 4 MK Baine (29517_CR38) 2020; 15 MD Robinson (29517_CR81) 2010; 26 C Zhong (29517_CR39) 2019; 446 M Ayers (29517_CR62) 2017; 127 S Hanzelmann (29517_CR82) 2013; 14 29517_CR10 J Cuzick (29517_CR84) 2011; 12 29517_CR53 CM Rudin (29517_CR4) 2019; 19 D Schreiber (29517_CR6) 2010; 116 29517_CR14 29517_CR13 E Elyada (29517_CR50) 2019; 9 TK Owonikoko (29517_CR74) 2020; 15 CL Christensen (29517_CR19) 2014; 26 N Ready (29517_CR58) 2019; 14 L Horn (29517_CR59) 2018; 379 JS Lim (29517_CR24) 2017; 545 A Augustyn (29517_CR45) 2014; 111 EG Bluemn (29517_CR16) 2017; 32 A Thomas (29517_CR52) 2016; 8 E Polley (29517_CR34) 2016; 108 DJ Wooten (29517_CR42) 2019; 15 A Thomas (29517_CR5) 2018; 154 DE Pefani (29517_CR41) 2016; 63 F Bottger (29517_CR23) 2019; 27 G Bindea (29517_CR60) 2013; 39 A Quintanal-Villalonga (29517_CR7) 2020; 17 D Anastassiou (29517_CR49) 2011; 11 A Thomas (29517_CR12) 2019; 14 CA Stewart (29517_CR21) 2020; 1 AH Wagner (29517_CR32) 2018; 9 29517_CR44 H Beltran (29517_CR17) 2016; 22 AF Farago (29517_CR28) 2019; 9 H Cai (29517_CR80) 2018; 14 RJ Cardnell (29517_CR72) 2017; 8 29517_CR48 Y Ren (29517_CR79) 2016; 7 L Cai (29517_CR66) 2021; 4 F Huang (29517_CR68) 2018; 28 J Xu (29517_CR47) 2009; 19 EE Gardner (29517_CR55) 2017; 31 AM Newman (29517_CR25) 2015; 12 AF Gazdar (29517_CR18) 1985; 45 HC Chung (29517_CR90) 2019; 79 G Mollaoglu (29517_CR43) 2017; 31 A Liberzon (29517_CR83) 2011; 27 A Thomas (29517_CR11) 2018; 36 AS Ireland (29517_CR31) 2020; 38 N Takahashi (29517_CR77) 2020; 26 |
| References_xml | – volume: 9 year: 2018 ident: CR32 article-title: Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer publication-title: Nat. Commun. doi: 10.1038/s41467-018-06162-9 – volume: 8 start-page: 73745 year: 2017 end-page: 73756 ident: CR36 article-title: Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.20572 – volume: 11 year: 2011 ident: CR49 article-title: Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo publication-title: BMC Cancer doi: 10.1186/1471-2407-11-529 – volume: 26 start-page: 2452 year: 2020 end-page: 2456 ident: CR77 article-title: Targeting DNA repair to drive immune responses: it’s time to reconsider the strategy for clinical translation publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3841 – volume: 45 start-page: 2913 year: 1985 end-page: 2923 ident: CR3 article-title: Establishment and identification of small cell lung-cancer cell-lines having classic and variant features publication-title: Cancer Res. – volume: 7 start-page: 32 year: 2018 end-page: 49 ident: CR15 article-title: Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes publication-title: Transl. Lung Cancer Res doi: 10.21037/tlcr.2018.02.02 – volume: 116 start-page: 1350 year: 2010 end-page: 1357 ident: CR6 article-title: Survival outcomes with the use of surgery in limited-stage small cell lung: cancer should its role be re-evaluated? publication-title: Cancer doi: 10.1002/cncr.24853 – volume: 45 start-page: 2924 year: 1985 end-page: 2930 ident: CR18 article-title: Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties publication-title: Cancer Res – volume: 14 start-page: 1397 year: 2018 end-page: 1407 ident: CR80 article-title: The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study publication-title: Future Oncol. doi: 10.2217/fon-2017-0706 – volume: 38 start-page: 60 year: 2020 end-page: 78.e12 ident: CR31 article-title: MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.05.001 – volume: 15 start-page: 1507 year: 2020 end-page: 1521 ident: CR65 article-title: Harnessing natural killer immunity in metastatic SCLC publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.05.008 – volume: 28 start-page: 369 year: 2018 end-page: 382 e5 ident: CR68 article-title: Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers publication-title: Cell Metab. doi: 10.1016/j.cmet.2018.06.005 – volume: 127 start-page: 2930 year: 2017 end-page: 2940 ident: CR62 article-title: IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade publication-title: J. Clin. Invest doi: 10.1172/JCI91190 – volume: 36 start-page: 17 year: 2019 end-page: 34 ident: CR8 article-title: Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.06.005 – volume: 1 start-page: 437 year: 2020 end-page: 451 ident: CR22 article-title: A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity publication-title: Nat. Cancer doi: 10.1038/s43018-020-0046-2 – volume: 9 start-page: 1102 year: 2019 end-page: 1123 ident: CR50 article-title: Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-19-0094 – volume: 27 start-page: 3345 year: 2019 end-page: 3358 e4 ident: CR23 article-title: Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.05.057 – volume: 15 start-page: 1823 year: 2020 end-page: 1835 ident: CR38 article-title: SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.09.009 – volume: 26 start-page: 139 year: 2010 end-page: 140 ident: CR81 article-title: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp616 – volume: 9 start-page: 1372 year: 2019 end-page: 1387 ident: CR28 article-title: Combination olaparib and temozolomide in relapsed small-cell lung cancer publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-19-0582 – volume: 31 start-page: 270 year: 2017 end-page: 285 ident: CR43 article-title: MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.12.005 – volume: 39 start-page: 782 year: 2013 end-page: 795 ident: CR60 article-title: Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer publication-title: Immunity doi: 10.1016/j.immuni.2013.10.003 – volume: 24 start-page: 1965 year: 2018 end-page: 1973 ident: CR57 article-title: Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-17-2655 – volume: 16 start-page: 464 year: 2021 end-page: 476 ident: CR75 article-title: YAP1 expression in sclc defines a distinct subtype with T-cell-inflamed phenotype publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.11.006 – volume: 524 start-page: 47 year: 2015 end-page: 53 ident: CR30 article-title: Comprehensive genomic profiles of small cell lung cancer publication-title: Nature doi: 10.1038/nature14664 – volume: 446 start-page: 133 year: 2019 end-page: 141 ident: CR39 article-title: Atoh1 and other related key regulators in the development of auditory sensory epithelium in the mammalian inner ear: function and interplay publication-title: Dev. Biol. doi: 10.1016/j.ydbio.2018.12.025 – volume: 8 start-page: 600 year: 2018 end-page: 615 ident: CR29 article-title: Genomic and functional fidelity of small cell lung cancer patient-derived xenografts publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-17-0935 – volume: 14 year: 2013 ident: CR82 article-title: GSVA: gene set variation analysis for microarray and RNA-seq data publication-title: BMC Bioinforma. doi: 10.1186/1471-2105-14-7 – ident: CR9 – volume: 7 start-page: 53245 year: 2016 end-page: 53253 ident: CR79 article-title: Prognostic effect of liver metastasis in lung cancer patients with distant metastasis publication-title: Oncotarget doi: 10.18632/oncotarget.10644 – volume: 7 year: 2017 ident: CR88 article-title: QuPath: Open source software for digital pathology image analysis publication-title: Sci. Rep. doi: 10.1038/s41598-017-17204-5 – ident: CR26 – volume: 4 start-page: 314 year: 2021 ident: CR66 article-title: Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer publication-title: Commun. Biol. doi: 10.1038/s42003-021-01842-7 – volume: 36 start-page: 1594 year: 2018 end-page: 1602 ident: CR11 article-title: Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.6915 – volume: 111 start-page: 14788 year: 2014 end-page: 14793 ident: CR45 article-title: ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1410419111 – volume: 14 start-page: 237 year: 2019 end-page: 244 ident: CR58 article-title: Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.10.003 – volume: 17 start-page: 765 year: 2017 end-page: 765 ident: CR2 article-title: Small-cell lung cancer: what we know, what we need to know and the path forward (vol 17, pg 725, 2017) publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.106 – volume: 14 start-page: 1447 year: 2019 end-page: 1457 ident: CR12 article-title: Durvalumab in combination with olaparib in patients with relapsed SCLC: Results from a phase II study publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2019.04.026 – volume: 28 start-page: 984 year: 2021 end-page: 999 ident: CR51 article-title: Cancer-associated fibroblasts: overview, progress, challenges, and directions publication-title: Cancer Gene Ther doi: 10.1038/s41417-021-00318-4 – volume: 154 start-page: 1284 year: 2018 end-page: 1290 ident: CR5 article-title: Characteristics and outcomes of small cell lung cancer detected by CT screening publication-title: Chest doi: 10.1016/j.chest.2018.07.029 – volume: 27 start-page: 1739 year: 2011 end-page: 1740 ident: CR83 article-title: Molecular signatures database (MSigDB) 3.0 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr260 – ident: CR14 – volume: 1711 start-page: 243 year: 2018 end-page: 259 ident: CR64 article-title: Profiling tumor infiltrating immune cells with CIBERSORT publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-7493-1_12 – ident: CR53 – volume: 39 start-page: 346 year: 2021 end-page: 360 e7 ident: CR27 article-title: Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.12.014 – volume: 379 start-page: 2220 year: 2018 end-page: 2229 ident: CR59 article-title: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa1809064 – ident: CR10 – volume: 1 start-page: 423 year: 2020 end-page: 436 ident: CR21 article-title: Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer publication-title: Nature – volume: 18 start-page: 99 year: 2004 end-page: 115 ident: CR46 article-title: Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation publication-title: Genes Dev. doi: 10.1101/gad.276304 – volume: 15 start-page: 274 year: 2020 end-page: 287 ident: CR74 article-title: Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2019.10.013 – volume: 19 start-page: 156 year: 2009 end-page: 172 ident: CR47 article-title: TGF-beta-induced epithelial to mesenchymal transition publication-title: Cell Res. doi: 10.1038/cr.2009.5 – volume: 15 start-page: e1007343 year: 2019 ident: CR42 article-title: Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers publication-title: PLoS Comput Biol. doi: 10.1371/journal.pcbi.1007343 – volume: 12 start-page: 453 year: 2015 end-page: 457 ident: CR25 article-title: Robust enumeration of cell subsets from tissue expression profiles publication-title: Nat. Methods doi: 10.1038/nmeth.3337 – volume: 131 start-page: e139929 year: 2021 ident: CR69 article-title: Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer publication-title: J Clin Invest doi: 10.1172/JCI139929 – volume: 32 start-page: 474 year: 2017 end-page: 489 e6 ident: CR16 article-title: Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.09.003 – ident: CR63 – volume: 19 start-page: 289 year: 2019 end-page: 297 ident: CR4 article-title: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0133-9 – volume: 1180 start-page: 31 year: 2014 end-page: 43 ident: CR85 article-title: Tissue processing and hematoxylin and eosin staining publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-1050-2_3 – volume: 113 start-page: E71 year: 2016 end-page: E80 ident: CR40 article-title: Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1517188113 – volume: 63 start-page: 156 year: 2016 end-page: 166 ident: CR41 article-title: TGF-beta targets the hippo pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear translocation publication-title: Mol. Cell doi: 10.1016/j.molcel.2016.05.012 – volume: 39 start-page: 5430 year: 2020 end-page: 5440 ident: CR54 article-title: A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels publication-title: Oncogene doi: 10.1038/s41388-020-1367-4 – ident: CR44 – volume: 17 year: 2016 ident: CR61 article-title: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures publication-title: Genome Biol. doi: 10.1186/s13059-016-1092-z – volume: 8 start-page: 73419 year: 2017 end-page: 73432 ident: CR72 article-title: Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies publication-title: Oncotarget doi: 10.18632/oncotarget.20621 – volume: 12 start-page: 245 year: 2011 end-page: 255 ident: CR84 article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70295-3 – ident: CR48 – ident: CR73 – volume: 79 start-page: CT073 year: 2019 end-page: CT073 ident: CR90 article-title: Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies publication-title: Cancer Res. – volume: 578 start-page: 94 year: 2020 end-page: 101 ident: CR71 article-title: The repertoire of mutational signatures in human cancer publication-title: Nature doi: 10.1038/s41586-020-1943-3 – volume: 16 start-page: 1259 year: 2016 end-page: 1272 ident: CR35 article-title: ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs publication-title: Cell Rep. doi: 10.1016/j.celrep.2016.06.081 – ident: CR13 – volume: 108 start-page: djw122 year: 2016 ident: CR34 article-title: Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djw122 – volume: 38 start-page: 229 year: 2020 end-page: 246.e13 ident: CR70 article-title: Emergence of a high-plasticity cell state during lung cancer evolution publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.012 – volume: 24 start-page: 235 year: 2017 end-page: 251 ident: CR87 article-title: Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research publication-title: Adv. Anat. Pathol. doi: 10.1097/PAP.0000000000000162 – volume: 383 start-page: 640 year: 2020 end-page: 649 ident: CR1 article-title: The effect of advances in lung-cancer treatment on population mortality publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1916623 – volume: 26 start-page: 909 year: 2014 end-page: 922 ident: CR19 article-title: Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.10.019 – volume: 33 start-page: 108296 year: 2020 ident: CR33 article-title: SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108296 – volume: 31 start-page: 286 year: 2017 end-page: 299 ident: CR55 article-title: Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.01.006 – volume: 201 start-page: 94 year: 2019 end-page: 102 ident: CR56 article-title: Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2019.05.009 – volume: 10 year: 2019 ident: CR89 article-title: An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma publication-title: Nat. Commun. doi: 10.1038/s41467-019-13043-2 – volume: 50 start-page: 6068 year: 1990 end-page: 6074 ident: CR20 article-title: A comparison of synaptophysin, chromogranin, and L-Dopa decarboxylase as markers for neuroendocrine differentiation in lung-cancer cell-lines publication-title: Cancer Res. – volume: 545 start-page: 360 year: 2017 end-page: 364 ident: CR24 article-title: Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer publication-title: Nature doi: 10.1038/nature22323 – volume: 32 start-page: 915 year: 2018 end-page: 928 ident: CR37 article-title: POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer publication-title: Genes Dev. doi: 10.1101/gad.314815.118 – volume: 17 start-page: 360 year: 2020 end-page: 371 ident: CR7 article-title: Lineage plasticity in cancer: a shared pathway of therapeutic resistance publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0340-z – volume: 4 start-page: 617 year: 2012 end-page: 620 ident: CR78 article-title: Specific organ metastases and survival in small cell lung cancer publication-title: Oncol. Lett. doi: 10.3892/ol.2012.792 – volume: 22 start-page: 298 year: 2016 end-page: 305 ident: CR17 article-title: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer publication-title: Nat. Med. doi: 10.1038/nm.4045 – volume: 8 start-page: 346fs12 year: 2016 ident: CR52 article-title: Small cell lung cancer: Time to revisit DNA-damaging chemotherapy publication-title: Sci. Transl. Med – volume: 25 start-page: 5107 year: 2019 end-page: 5121 ident: CR67 article-title: MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-4140 – volume: 45 start-page: 2924 year: 1985 end-page: 2930 ident: CR86 article-title: Characterization of variant subclasses of cell-lines derived from small cell lung-cancer having distinctive biochemical, morphological, and growth-properties publication-title: Cancer Res. – volume: 4 start-page: 998 year: 2014 end-page: 1013 ident: CR76 article-title: Patient-derived xenograft models: an emerging platform for translational cancer research publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-14-0001 – volume: 38 start-page: 60 year: 2020 ident: 29517_CR31 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.05.001 – volume: 11 year: 2011 ident: 29517_CR49 publication-title: BMC Cancer doi: 10.1186/1471-2407-11-529 – volume: 116 start-page: 1350 year: 2010 ident: 29517_CR6 publication-title: Cancer doi: 10.1002/cncr.24853 – volume: 1180 start-page: 31 year: 2014 ident: 29517_CR85 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-1050-2_3 – volume: 39 start-page: 782 year: 2013 ident: 29517_CR60 publication-title: Immunity doi: 10.1016/j.immuni.2013.10.003 – volume: 45 start-page: 2913 year: 1985 ident: 29517_CR3 publication-title: Cancer Res. – volume: 8 start-page: 600 year: 2018 ident: 29517_CR29 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-17-0935 – volume: 38 start-page: 229 year: 2020 ident: 29517_CR70 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.012 – volume: 201 start-page: 94 year: 2019 ident: 29517_CR56 publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2019.05.009 – volume: 8 start-page: 346fs12 year: 2016 ident: 29517_CR52 publication-title: Sci. Transl. Med – volume: 14 year: 2013 ident: 29517_CR82 publication-title: BMC Bioinforma. doi: 10.1186/1471-2105-14-7 – ident: 29517_CR53 doi: 10.2139/ssrn.3891794 – volume: 32 start-page: 474 year: 2017 ident: 29517_CR16 publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.09.003 – volume: 16 start-page: 1259 year: 2016 ident: 29517_CR35 publication-title: Cell Rep. doi: 10.1016/j.celrep.2016.06.081 – ident: 29517_CR48 doi: 10.1038/celldisc.2015.26 – volume: 14 start-page: 237 year: 2019 ident: 29517_CR58 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.10.003 – volume: 12 start-page: 245 year: 2011 ident: 29517_CR84 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70295-3 – volume: 524 start-page: 47 year: 2015 ident: 29517_CR30 publication-title: Nature doi: 10.1038/nature14664 – volume: 4 start-page: 314 year: 2021 ident: 29517_CR66 publication-title: Commun. Biol. doi: 10.1038/s42003-021-01842-7 – volume: 16 start-page: 464 year: 2021 ident: 29517_CR75 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.11.006 – ident: 29517_CR73 doi: 10.1038/s41467-019-11371-x – volume: 36 start-page: 17 year: 2019 ident: 29517_CR8 publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.06.005 – volume: 22 start-page: 298 year: 2016 ident: 29517_CR17 publication-title: Nat. Med. doi: 10.1038/nm.4045 – volume: 33 start-page: 108296 year: 2020 ident: 29517_CR33 publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108296 – volume: 50 start-page: 6068 year: 1990 ident: 29517_CR20 publication-title: Cancer Res. – volume: 18 start-page: 99 year: 2004 ident: 29517_CR46 publication-title: Genes Dev. doi: 10.1101/gad.276304 – volume: 28 start-page: 984 year: 2021 ident: 29517_CR51 publication-title: Cancer Gene Ther doi: 10.1038/s41417-021-00318-4 – volume: 4 start-page: 998 year: 2014 ident: 29517_CR76 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-14-0001 – volume: 7 start-page: 53245 year: 2016 ident: 29517_CR79 publication-title: Oncotarget doi: 10.18632/oncotarget.10644 – volume: 36 start-page: 1594 year: 2018 ident: 29517_CR11 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.6915 – volume: 17 year: 2016 ident: 29517_CR61 publication-title: Genome Biol. doi: 10.1186/s13059-016-1092-z – volume: 31 start-page: 270 year: 2017 ident: 29517_CR43 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.12.005 – volume: 24 start-page: 1965 year: 2018 ident: 29517_CR57 publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-17-2655 – ident: 29517_CR14 doi: 10.1038/s41467-021-24164-y – volume: 26 start-page: 2452 year: 2020 ident: 29517_CR77 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3841 – ident: 29517_CR13 doi: 10.1016/j.ccell.2021.02.014 – volume: 27 start-page: 1739 year: 2011 ident: 29517_CR83 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr260 – volume: 79 start-page: CT073 year: 2019 ident: 29517_CR90 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2019-CT073 – volume: 63 start-page: 156 year: 2016 ident: 29517_CR41 publication-title: Mol. Cell doi: 10.1016/j.molcel.2016.05.012 – volume: 31 start-page: 286 year: 2017 ident: 29517_CR55 publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.01.006 – volume: 8 start-page: 73419 year: 2017 ident: 29517_CR72 publication-title: Oncotarget doi: 10.18632/oncotarget.20621 – volume: 12 start-page: 453 year: 2015 ident: 29517_CR25 publication-title: Nat. Methods doi: 10.1038/nmeth.3337 – volume: 8 start-page: 73745 year: 2017 ident: 29517_CR36 publication-title: Oncotarget doi: 10.18632/oncotarget.20572 – volume: 19 start-page: 156 year: 2009 ident: 29517_CR47 publication-title: Cell Res. doi: 10.1038/cr.2009.5 – volume: 1711 start-page: 243 year: 2018 ident: 29517_CR64 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-7493-1_12 – volume: 15 start-page: 1823 year: 2020 ident: 29517_CR38 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.09.009 – volume: 127 start-page: 2930 year: 2017 ident: 29517_CR62 publication-title: J. Clin. Invest doi: 10.1172/JCI91190 – volume: 27 start-page: 3345 year: 2019 ident: 29517_CR23 publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.05.057 – volume: 4 start-page: 617 year: 2012 ident: 29517_CR78 publication-title: Oncol. Lett. doi: 10.3892/ol.2012.792 – volume: 17 start-page: 765 year: 2017 ident: 29517_CR2 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.106 – ident: 29517_CR44 – volume: 9 start-page: 1372 year: 2019 ident: 29517_CR28 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-19-0582 – volume: 17 start-page: 360 year: 2020 ident: 29517_CR7 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0340-z – volume: 39 start-page: 5430 year: 2020 ident: 29517_CR54 publication-title: Oncogene doi: 10.1038/s41388-020-1367-4 – volume: 26 start-page: 139 year: 2010 ident: 29517_CR81 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp616 – volume: 578 start-page: 94 year: 2020 ident: 29517_CR71 publication-title: Nature doi: 10.1038/s41586-020-1943-3 – volume: 7 start-page: 32 year: 2018 ident: 29517_CR15 publication-title: Transl. Lung Cancer Res doi: 10.21037/tlcr.2018.02.02 – ident: 29517_CR63 doi: 10.7554/eLife.49020 – volume: 154 start-page: 1284 year: 2018 ident: 29517_CR5 publication-title: Chest doi: 10.1016/j.chest.2018.07.029 – ident: 29517_CR9 doi: 10.1101/2020.09.13.291328 – volume: 14 start-page: 1397 year: 2018 ident: 29517_CR80 publication-title: Future Oncol. doi: 10.2217/fon-2017-0706 – volume: 446 start-page: 133 year: 2019 ident: 29517_CR39 publication-title: Dev. Biol. doi: 10.1016/j.ydbio.2018.12.025 – volume: 25 start-page: 5107 year: 2019 ident: 29517_CR67 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-4140 – volume: 108 start-page: djw122 year: 2016 ident: 29517_CR34 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djw122 – volume: 111 start-page: 14788 year: 2014 ident: 29517_CR45 publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1410419111 – volume: 15 start-page: 1507 year: 2020 ident: 29517_CR65 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2020.05.008 – volume: 383 start-page: 640 year: 2020 ident: 29517_CR1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1916623 – volume: 26 start-page: 909 year: 2014 ident: 29517_CR19 publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.10.019 – volume: 1 start-page: 437 year: 2020 ident: 29517_CR22 publication-title: Nat. Cancer doi: 10.1038/s43018-020-0046-2 – volume: 113 start-page: E71 year: 2016 ident: 29517_CR40 publication-title: Proc. Natl Acad. Sci. doi: 10.1073/pnas.1517188113 – volume: 7 year: 2017 ident: 29517_CR88 publication-title: Sci. Rep. doi: 10.1038/s41598-017-17204-5 – volume: 545 start-page: 360 year: 2017 ident: 29517_CR24 publication-title: Nature doi: 10.1038/nature22323 – volume: 39 start-page: 346 year: 2021 ident: 29517_CR27 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.12.014 – volume: 379 start-page: 2220 year: 2018 ident: 29517_CR59 publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa1809064 – volume: 28 start-page: 369 year: 2018 ident: 29517_CR68 publication-title: Cell Metab. doi: 10.1016/j.cmet.2018.06.005 – volume: 9 year: 2018 ident: 29517_CR32 publication-title: Nat. Commun. doi: 10.1038/s41467-018-06162-9 – volume: 45 start-page: 2924 year: 1985 ident: 29517_CR18 publication-title: Cancer Res – volume: 10 year: 2019 ident: 29517_CR89 publication-title: Nat. Commun. doi: 10.1038/s41467-019-13043-2 – volume: 15 start-page: 274 year: 2020 ident: 29517_CR74 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2019.10.013 – ident: 29517_CR10 doi: 10.14694/EdBook_AM.2015.35.92 – volume: 19 start-page: 289 year: 2019 ident: 29517_CR4 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0133-9 – ident: 29517_CR26 doi: 10.1101/2021.01.22.427865 – volume: 131 start-page: e139929 year: 2021 ident: 29517_CR69 publication-title: J Clin Invest doi: 10.1172/JCI139929 – volume: 45 start-page: 2924 year: 1985 ident: 29517_CR86 publication-title: Cancer Res. – volume: 32 start-page: 915 year: 2018 ident: 29517_CR37 publication-title: Genes Dev. doi: 10.1101/gad.314815.118 – volume: 15 start-page: e1007343 year: 2019 ident: 29517_CR42 publication-title: PLoS Comput Biol. doi: 10.1371/journal.pcbi.1007343 – volume: 14 start-page: 1447 year: 2019 ident: 29517_CR12 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2019.04.026 – volume: 1 start-page: 423 year: 2020 ident: 29517_CR21 publication-title: Nature – volume: 9 start-page: 1102 year: 2019 ident: 29517_CR50 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-19-0094 – volume: 24 start-page: 235 year: 2017 ident: 29517_CR87 publication-title: Adv. Anat. Pathol. doi: 10.1097/PAP.0000000000000162 |
| SSID | ssj0000391844 |
| Score | 2.5957298 |
| Snippet | Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and... Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2023 |
| SubjectTerms | 38 38/91 45 45/23 631/67/1612/2143 631/67/70 692/4028/67/1612/2143 692/53 ASCL1 protein Beta2 protein Cell differentiation Chemical compounds Chemotherapy Chromatin DNA damage Gene Expression Regulation, Neoplastic Genomics Heterogeneity Histology Humanities and Social Sciences Humans Immunotherapy Lung cancer Lung Neoplasms - pathology Math1 protein Metastases Metastasis multidisciplinary Mutation Neuroendocrine Tumors - genetics Patients Pharmacology Phenotypes Science Science (multidisciplinary) Small cell lung carcinoma Small Cell Lung Carcinoma - pathology Transcription Transcription Factors - metabolism Transcriptomes Transcriptomics Tumors Xenografts Xenotransplantation Yes-associated protein |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFA4yILgR39YZJYI7LZMmaR5LFYeLoKsRZhfSPPDCnVamHcV_P-ekvde5Pjcu26Yl5Hw55ztN8h1CXgiDYbGJdWRR1DKKrvY6Q7KSggmaZSYyruh--KhWn-T7s_bsWqkv3BM2ywPPA3fMO81U5l0CMMrcRtMEbVvts2UheRHQ-0LMu5ZMFR8sLKQucjklw4Q5HmXxCbh5nQOr0LXdi0RFsP93LPPXzZI_rZiWQHRyh9xeGCR9Pff8LrmR-nvk5lxT8vt98m2FG1wGwEUCgk2HTItkZerjEPCkH50wOm19BXyoHCka6bqn52nyeLUOdDz3mw3Fv_p0A-6ABgTHxUh9H-kixVpHAO_XFGkppjM-IKcn707fruqlukIdIGmZam9ltCmkoAS3mrfZhqiy7TqTWq6DZz7LZHkGRsGMDEHpmK3UPOLZVSAVD8lBP_TpMaGd6toIaV0TspIZUrgInM6YYGJnTLJNRZrtQLuwKI9jAYyNKyvgwrjZOA6M44pxnK3Iy907X2bdjb-2foP227VEzexyA5DkFiS5fyGpIkdb67tlIo-Oq7aIwBlekee7xzAF0QK-T8Pl3MYoyYSsyKMZLLueiFZiBgtv6z0Y7XV1_0m__lxkvoGpGfhsRV5tAfejW38eiif_YygOyS2OMwU1Le0ROZguLtNTIF9T96zMsytxqCzj priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k2gICNxg6iJ7cT2CQGiWiHBqUh7sxw_YKVtUjYpVf89M86jWh49JnEiO_PwN_b4G0Jec4XTYulzX3ieC8-b3MoIwUpwyskiFjziju6Xr_Xqm_i8rtbTgls_pVXOPjE5at85XCM_YnWV2LgUe3f2M8eqUbi7OpXQuEluIXUZpnTJtVzWWJD9XAkxnZUpuDrqRfIMmMLOAFvIXO_NR4m2_19Y8--UyT_2TdN0dHyP3J1wJH0_Cv4-uRHaB-T2WFny8iG5WGGaSwfaEQBm0y7SRFwZWhgonvejA85Rs8eAD6WDRT3dtPQ0DBavNo72p3a7pbi2T7fgFKhDFdn11LaeToSsuQcV_hU8TSV1-kfk5PjTycdVPtVYyB2ELkNutfA6uOBqzrRkVdTO11E3jQoVk84WNoqgWQRcUSjhXC191EIyjydYAVo8Jgdt14anhDZ1U3kI7koXaxEhkPOA7JRyyjdKBV1mpJx_tHET_ziWwdiatA_OlRmFY0A4JgnH6Iy8Wd45G9k3rm39AeW3tETm7HSj2303kyEa1siijqwJ4NxErLwqndSVtFEXLljuMnI4S99M5tybK-XLyKvlMRgiSsC2oTsf26haFFxk5MmoLEtPeCUwjoW35Z4a7XV1_0m7-ZHIvgGvKfhsRt7OCnfVrf__imfXj-I5ucPQBpCzUh-Sg2F3Hl4AuBqal8mCfgMibSPq priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LixQxEA7riuBFfNu6SgRv2tiTpPM46uAyCHpaYW8hnYcOzHbLdK_iv7cq_ZDRVfDYnQchVZV8lVR9IeQF17gtrkIZqsBLEXhTOpXAWYlee1Wliie80f3wUW4-iffn9fkRYXMuTA7az5SWeZmeo8Ne9yKbNMaeMwAFqjTXyHWkbketXsv1cq6CjOdaiCk_puL6iqYHe1Cm6r8KX_4ZJvnbXWnegk5vk1sTdqRvxtHeIUexvUtujK9J_rhHvm8wtKUDjYgArWmXaCarjG3oPOb40QH3pXmVgI5yMlFPty29iIPDr62n_YXb7Sie59MdLATUo1rse-raQCcS1jKA2n6LgeZndPr75Oz03dl6U07vKpQe3JWhdEYEE330kjOjWJ2MDzKZptGxZsq7yiURDUuAJSotvJcqJCMUC5i1CnDiATluuzY-IrSRTR3AoVv5JEUC5y0AmtPa69BoHc2qIKt5oq2fOMfx6YudzXffXNtROBaEY7NwrCnIy6XN15Fx45-136L8lprIlp1_dPvPdtIeyxpVycSaCAuaSHXQK69MrVwylY-O-4KczNK3kwn3lsk6079pVpDnSzEYH0rAtbG7HOtoKSouCvJwVJZlJLwW6LtCa3WgRgdDPSxpt18ywTdgNA3dFuTVrHC_hvX3qXj8f9WfkJsMbQJ5K80JOR72l_EpAKyheZYt6ieLFSHA priority: 102 providerName: Springer Nature |
| Title | Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models |
| URI | https://link.springer.com/article/10.1038/s41467-022-29517-9 https://www.ncbi.nlm.nih.gov/pubmed/35440132 https://www.proquest.com/docview/2652408582 https://www.proquest.com/docview/2652864034 https://pubmed.ncbi.nlm.nih.gov/PMC9018864 https://doaj.org/article/2b706f2be3074f5d81c7957af90cea3c |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_tQ6C9IL4JjMpIvEEgcZzYfkCoq1aqSpsQbFLfosQfUKlLtqYD9t9zdpKiQuGBl1RJnNTy3fl-F_t-B_AyEc4txjrUkU5CppMyLLjFYMUooXhko8S6Fd2T02xyzqazdLYDfbmjbgCbraGdqyd1vly8-XF18x4N_l2bMi7eNsybu9uXThEw8FDuwj56Ju4M9aSD-35mTiQGNKzLndn-6AHcTlLmog664ao8o_82GPrnbsrfllS9pxrfhTsdxCTDVifuwY6p7sOttujkzQP4PnE7YGpUHIMInNSWeE5LU-lauVRAsnLuq59M8EU-56gh84pcmFXhzuaKNBfFYkHcZ3-ywPmCKKc9y4YUlSYdV2uoUbu_GU18tZ3mIZyNj89Gk7ArvxAqjGpWYSGZlkYZlSVUcppaqXRmZVkKk1KuiqiwzEhqEXJEgimVcW0l41S75FZEHY9gr6or8wRImZWpxrgvVjZjFmM8jaBPCCV0KYSRcQBxP9C56qjJXYWMRe6XyBORt3LKUU65l1MuA3i1fuayJeb4Z-sjJ791S0eq7S_Uyy95Z6M5LXmUWVoanPeYTbWIFZcpL6yMlCkSFcBhL_28V9ScZqlniRM0gBfr22ijTgJFZerrto3IWJSwAB63yrLuSa9sAfANNdro6uadav7V84AjlBP42gBe9wr3q1t_H4qn__1Hz-CAOktxTJfyEPZWy2vzHCHZqhzALp9xPIrxhwHsD4fTz1P8PTo-_fgJr46y0cB_7Bh4e_wJQOY7LA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLaqIgQXxE5KASPBCaImjhPbB4TYqildToM0NyvxAiNNk3aSUvVH8R95z0mmGpbeekziRI7f7uf3PUJeZRLNYmpjm9gs5jar4lJ4CFackUYkPsk8ZnQPj4rJN_51ls82yK-xFgaPVY46MShq2xjcI99hRR7QuCR7f3IaY9cozK6OLTR6tth3F-cQsrXv9j4DfV8ztvtl-mkSD10FYgPOeheXilvljDNFxpRguVfGFl5VlXQ5E6ZMSs-dYh4saSK5MYWwXnHBLNZsMsQ5AI1_A-xuggIlZmK1pYNg65LzoTQnyeROy4MiwhPzDFwZEas18xe6BPzLtf37hOYfadpg_XbvkjuD20o_9Hx2j2y4-j652TeyvHhAzid4qqYBZnTg1dPG04CT6WpYVywvpB2axFFBwYdCHVNL5zU9dl2JV3ND2-NysaCYSqAL0EHUIEcuW1rWlg74r7EFifnpLA0dfNqHZHodi_-IbNZN7Z4QWhVVbiGWTI0vuIe40YIjKaWRtpLSqTQi6bjQ2gxw59h1Y6FD2j2TuieOBuLoQBytIvJm9c5JD_Zx5eiPSL_VSATqDjea5Xc9yL1mlUgKzyoHupT73MrUCJWL0qvEuDIzEdkeqa8H7dHqS16PyMvVY5B7pEBZu-asHyMLnmQ8Io97ZlnNJMs5hs3wtlhjo7Wprj-p5z8Ctji4hxI-G5G3I8NdTuv_S7F19V-8ILcm08MDfbB3tP-U3GYoDwiXqbbJZrc8c8_Ar-uq50GaKNHXLL2_Ab72YHM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIhAXxJtAASPBCaJNHCe2DwgBZbWlUHEo0t6sxA9YaZuUTUrVn8a_Y8ZJtloevfW4GydyPO_MzDeEPM8kmsXUxjaxWcxtVsWl8BCsOCONSHySeczofj4oZl_5x3k-3yK_xl4YLKscdWJQ1LYx-I18woo8oHFJNvFDWcSX3emb4x8xTpDCTOs4TqNnkX13dgrhW_t6bxdo_YKx6YfD97N4mDAQG3Dcu7hU3CpnnCkypgTLvTK28KqqpMuZMGVSeu4U82BVE8mNKYT1igtmsX-TIeYBaP8rIstTFDExF-vPOwi8Ljkf2nSSTE5aHpQSVs8zcGtErDZMYZgY8C839-9qzT9StsESTm-SG4MLS9_2PHeLbLn6NrnaD7U8u0NOZ1hh0wBjOvDwaeNpwMx0NZwxthrSDs3jqKzgQaGnqaWLmh65rsRfC0Pbo3K5pJhWoEvQR9Qgd65aWtaWDliwsQXp-eksDdN82rvk8DIO_x7ZrpvaPSC0KqrcQlyZGl9wDzGkBadSSiNtJaVTaUTS8aC1GaDPcQLHUocUfCZ1TxwNxNGBOFpF5OX6nuMe-OPC1e-QfuuVCNod_mhW3_SgAzSrRFJ4VjnQq9znVqZGqFyUXiXGlZmJyM5IfT1oklaf831Enq0vgw5ACpS1a076NbLgScYjcr9nlvVOspxjCA13iw022tjq5pV68T3gjIOrKOGxEXk1Mtz5tv5_FA8vfoun5BrIrf60d7D_iFxnKA6InKl2yHa3OnGPwcXrqidBmCjRlyy8vwEj-2Sp |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterogeneity+of+neuroendocrine+transcriptional+states+in+metastatic+small+cell+lung+cancers+and+patient-derived+models&rft.jtitle=Nature+communications&rft.au=Lissa%2C+Delphine&rft.au=Takahashi%2C+Nobuyuki&rft.au=Desai%2C+Parth&rft.au=Manukyan%2C+Irena&rft.date=2022-04-19&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=13&rft_id=info:doi/10.1038%2Fs41467-022-29517-9&rft_id=info%3Apmid%2F35440132&rft.externalDocID=PMC9018864 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |